Noxopharm Ltd. · ASX:NOX
Noxopharm — Shareholder Meeting (September 2019)
29 slides from Noxopharm's shareholder meeting presentation, Sep 16, 2019
Slide 1: Noxopharm EGM Chairman's Address and Presentation
Date: 16 September 2019 Sydney, Australia For personal use only ASX Limited 20 Bridge Street SYDNEY NSW 2000 NOXOPHARM EGM CHAIRMAN’S ADDRESS AND PRESENTATION • Chairman’s Address featuring short-term and medium-term funding strategies ahead of proposed U.S. listing • Presentation detailing clinical
Slide 2: Forward Looking Statements
Forward Looking Statements For personal use only This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “pr
Slide 3: Chairman's Address
Chairman’s Address For personal use only This EGM has been called to seek shareholder approval to provide the company with further funding capacity with a facility with a potential total value of A$26 million. I am going to focus in this address on 3 major topics. The first is the short- and medium-
Slide 4: Chairman's Address (continued)
For personal use only I want to emphasise that if at any stage the Board believes it is in the best interests of the Company to vary this bridging financing arrangement, then it will do so. We last raised capital 16 months ago. Since then, and prior to the current funding facility, the share price h
Slide 5: Chairman's Address (continued)
in these two sets of data; the novelty being in putting them together into the one report. We had For personal use only been informed that this data would not be made public until early-November, but we have discovered in the last 24 hours that it has in fact been made public, which means we will ne
Slide 6: Extraordinary General Meeting, Noxopharm Limited
September 2019 Extraordinary General Meeting For personal use only Noxopharm Limited Veyonda® DISCOVER DEVELOP DELIVER ASX: NOX © 2019 Noxopharm Ltd. All rights reserved.
Slide 7: Disclaimer
Disclaimer This presentation has been prepared by Noxopharm Limited (NOX or the Company). It should not be considered as an offer or invitation to subscribe for or purchase any shares in NOX or as an inducement to purchase any shares in NOX. No agreement to subscribe for securities in the NOX will b
Slide 8: The Opportunity
For personal use only The Opportunity © 2019 Noxopharm Ltd. All rights reserved.
Slide 9: The Opportunity for Veyonda in prostate cancer is huge
The Opportunity for Veyonda®* in the management of prostate cancer is huge For personal use only According to Australian and U.S. Govt sources: • 1 in 7 men will be diagnosed with PC by age 85 • New cases annually 19,000 (Aust) 175,000 (U.S.) • Deaths from prostate cancer annually 3,300 (Aust) 31,00
Slide 10: Prostate Cancer – four main stages
Prostate Cancer – four main stages For personal use only Stage I Stage II The cancer is small and confined to the The cancer is still confined to the prostate but is large prostate. enough to be detected by physical examination. Stage III Stage IV The cancer has spread beyond the prostate into The c
Slide 11: Prostate Cancer Treatment Options
Prostate Cancer Treatment Options Course of Disease and Treatment Journey for Stage I - IV Prostate Cancer use only Surgery and/or Chemical Chemo- Palliative therapy phase death local castration & Androgen therapy receptor radiotherapy therapy inhibitors Rising PSA For personal Hormone-sensitive Hor
Slide 12: Proposed Uses of Veyonda
Proposed Uses of Veyonda®* use only Aim is to use a combination of radiation and drug to restore the LuPIN death ability of the immune system DARRT to fight the cancer. Rising PSA At the very least For personal seeking to convert an aggressive DARRT cancer into a Palliative therapy phase chronic, sl
Slide 13: Veyonda DARRT
For personal use only Veyonda®️ DARRT © 2019 Noxopharm Ltd. All rights reserved.
Slide 14: Proposed Uses of Veyonda: DARRT
Proposed Uses of Veyonda®* DARRT use only death Rising PSA For personal Palliative therapy phase Hormone-sensitive Hormone-refractory Non-metastatic Metastatic * Veyonda®️ (NOX66/idronoxil) has yet to receive marketing approval © 2019 Noxopharm Ltd. All rights reserved.
Slide 15: DARRT – Late-stage cancer
For personal use only DARRT – Late-stage cancer Characteristics of late-stage, What would the Company, patients, doctors metastatic, castrate-resistant and regulators be likely to regard as a prostate cancer (mCRPC) worthwhile treatment in late-stage mCRPC? • Progressive disease Delivering in a sign
Slide 16: DARRT-1 Clinical data to date highly encouraging
DARRT-1 Clinical data to date highly encouraging For personal use only Part A Part B (Dose-finding: 400/800/1200 mg) (Dose-expansion: 1200 mg) 14 patients 11 patients 6 months FINAL 3 months INTERIM • 5/14 (36%) with PSA response at • 6/11 (55%) PSA response rate* any time * 6-month data expected la
Slide 17: Proposed Uses of Veyonda: DARRT
Proposed Uses of Veyonda®* DARRT use only death Rising PSA For personal Palliative therapy phase Hormone-sensitive Hormone-refractory Non-metastatic Metastatic * Veyonda®️ (NOX66/idronoxil) has yet to receive marketing approval © 2019 Noxopharm Ltd. All rights reserved.
Slide 18: DARRT – Early-stage cancer
DARRT – Early-stage cancer For personal use only Potential benefits for early- • Short courses of Veyonda®️* stage prostate cancer: • Veyonda®️ self-administered • Lower dosage of radiation less damaging to bowel and • Short course of radiotherapy bladder (lower rates of infection and treatment- • W
Slide 19: Veyonda LuPIN
For personal use only Veyonda®️ LuPIN © 2019 Noxopharm Ltd. All rights reserved.
Slide 20: Proposed Uses of Veyonda: LuPIN
Proposed Uses of Veyonda®* LuPIN use only death Rising PSA For personal Palliative therapy phase Hormone-sensitive Hormone-refractory Non-metastatic Metastatic * Veyonda®️ (NOX66/idronoxil) has yet to receive marketing approval © 2019 Noxopharm Ltd. All rights reserved.
Slide 21: LuPIN - 177Lutetium-PSMA-617 + Veyonda
LuPIN - 177Lutetium-PSMA-617 + Veyonda®* For personal use only Seeking to show that combination Interim data (July 2019) versus 177Lutetium-PSMA-617 alone Dose-finding: 400/800mg leads to a significant increase in ….. 16 patients • PSA responses (> 50% decline) • 10/16 (69%) PSA rate overall • 9/16
Slide 22: Outlook and Next Steps
For personal use only Outlook and Next Steps © 2019 Noxopharm Ltd. All rights reserved.
Slide 23: Upcoming Results
Upcoming Results Upcoming clinical data reports For personal use only 6-month, cohort 4: 1200 mg Veyonda®️* (11 patients) DARRT-1 • PSA response rate • Pain response rate • Progression-free survival • Overall tumour response (RECIST) Data expected late-November 2019 * Veyonda®️ (NOX66/idronoxil) has
Slide 24: Upcoming Results: LuPIN
Upcoming Results Upcoming clinical data reports For personal use only 177Lu-PSMA-617 alone LuPIN vs 177Lu-PSMA-617 + Veyonda® Comparison of two previously published sets of data: 177Lu-PSMA-617 alone https://www.ncbi.nlm.nih.gov/pubmed/30425003 177Lu-PSMA-617 + Veyonda https://www.noxopharm.com/site
Slide 25: LuPIN - 177Lutetium-PSMA-617 + Veyonda
LuPIN - 177Lutetium-PSMA-617 + Veyonda®* 177lut-PSMA alone 177lut-PSMA + Veyonda®️ For personal use only No. patients 14 16 Median PSA (ng/ml) 88 147 PSA response (>50% fall) 36% 69% PFS (months) 2.0 8.4 Complete 4 cycles 21% 69% No significant adverse treatment-related events reported Accepted for
Slide 26: The Veyonda Radiotherapy Program
The Veyonda® Radiotherapy Program For personal use only Late-stage Multi-centre, multi-national, metastatic, randomised controlled study DARRT castration- Veyonda®* + palliative EBRT resistant prostate versus palliative RT alone cancer Early-stage, hormone- Phase 1 study DARRT sensitive prostate Fir
Slide 27: Managing the Opportunity
For personal use only Managing the Opportunity © 2019 Noxopharm Ltd. All rights reserved.
Slide 28: Managing the Opportunity
Managing the Opportunity For personal use only Putting an experienced team in place, both at executive and Board level Having experienced advisors, both CRO and Medical Advisory Boards (both Australian and U.S.) Proposed dual U.S. listing H1 2020 + IPO to raise funding for extensive clinical trial p
Slide 29: Noxopharm Limited
For personal use only Noxopharm Limited www.noxopharm.com Veyonda® DISCOVER DEVELOP DELIVER ASX: NOX © 2019 Noxopharm Ltd. All rights reserved.